Preferential up-regulation of osteopontin in primary central nervous system lymphoma does not correlate with putative receptor CD44v6 or CD44H expression

Human Pathology

Volumn 44, Issue 4, 2013, Pages 606-611

  Yuan, Ji ^a   Gu, Keni ^b   He, Jianqing ^c   Sharma, Suash ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b University Hospital Augusta   (United States)

^c SICHUAN UNIVERSITY   (China)

Author keywords

CD44H; CD44v6; Osteopontin; Primary central nervous system lymphoma; SPP1

Indexed keywords

CD44H ANTIGEN; CD44V6 ANTIGEN; HERMES ANTIGEN; KI 67 ANTIGEN; OSTEOPONTIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; GERMINAL CENTER; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; OVERALL SURVIVAL; PATHOGENESIS; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR CELL;

ANTIGENS, CD44; CELL ADHESION; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; KI-67 ANTIGEN; LYMPH NODES; LYMPHOMA; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; OSTEOPONTIN; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84875217248     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.07.007     Document Type: Article

References (35)

1. C.P. Hans, D.D. Weisenburger, and T.C. Greiner Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 103 2004 275 282
2. S. Camilleri-Broet, E. Criniere, and P. Broet A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases Blood 107 2006 190 196
3. C.H. Lin, K.T. Kuo, and S.S. Chuang Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin Clin Cancer Res 12 2006 1152 1156
4. F.H. Hochberg, and D.C. Miller Primary central nervous system lymphoma J Neurosurg 68 1988 835 853
5. D.D. Hu, E.C. Lin, N.L. Kovach, J.R. Hoyer, and J.W. Smith A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5 J Biol Chem 270 1995 26232 26238
6. G.F. Weber, S. Ashkar, M.J. Glimcher, and H. Cantor Receptor-ligand interaction between CD44 and osteopontin (Eta-1) Science 271 1996 509 512
7. R. Stauder, and U. Günthert CD44 isoforms - impact on lymphocyte activation and differentiation Immunologist 3 1995 78 83
8. U. Günthert, and B. Johansson CD44-a protein family involved in autoimmune diseases and apoptosis Immunologist 8 2001 106 109
9. G.H. Yang, J. Fan, and Y. Xu Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection Oncologist 13 2008 1155 1165
10. T. Ue, H. Yokozaki, and Y. Kitadai Co-expression of osteopontin and CD44v9 in gastric cancer Int J Cancer 79 1998 127 132
11. R. Stauder, W. Eisterer, J. Thaler, and U. Gunthert CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor Blood 85 1995 2885 2899
12. M. Gotte, and G.W. Yip Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective Cancer Res 66 2006 10233 10237
13. V.J. Wielenga, R. van der Neut, G.J. Offerhaus, and S.T. Pals CD44 glycoproteins in colorectal cancer: expression, function, and prognostic value Adv Cancer Res 77 2000 169 187
14. H. Chagan-Yasutan, K. Tsukasaki, and Y. Takahashi Involvement of osteopontin and its signaling molecule CD44 in clinicopathological features of adult T cell leukemia Leuk Res 35 2011 1484 1490
15. H.W. Tun, D. Personett, and K.A. Baskerville Pathway analysis of primary central nervous system lymphoma Blood 111 2008 3200 3210
16. J.L. Rubenstein, A. Shen, T.T. Batchelor, C. Kadoch, P. Treseler, and M.A. Shuman Differential gene expression in central nervous system lymphoma Blood 113 2009 266 267 [author reply 267-8]
17. H. Inagaki, S. Banno, A. Wakita, R. Ueda, and T. Eimoto Prognostic significance of CD44v6 in diffuse large B-cell lymphoma Mod Pathol 12 1999 546 552
18. R. Ristamaki, H. Joensuu, K.O. Soderstrom, and S. Jalkanen CD44v6 expression in non-Hodgkin's lymphoma: an association with low histological grade and poor prognosis J Pathol 176 1995 259 267
19. A. Tzankov, A.C. Pehrs, and A. Zimpfer Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases J Clin Pathol 56 2003 747 752
20. S. Nagel, P. Hirschmann, S. Dirnhofer, U. Gunthert, and A. Tzankov Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an International Prognostic Index and C-MYC gene status-independent predictor of poor outcome in diffuse large B-cell lymphomas Exp Hematol 38 2010 38 45
21. E. Horst, C.J. Meijer, T. Radaszkiewicz, G.J. Ossekoppele, J.H. Van Krieken, and S.T. Pals Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54) Leukemia 4 1990 595 599
22. G. Salles, M. Zain, W.M. Jiang, V.A. Boussiotis, and M.A. Shipp Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies Blood 82 1993 3539 3547
23. H.J. Terpe, R. Koopmann, B.A. Imhof, and U. Gunthert Expression of integrins and CD44 isoforms in non-Hodgkin's lymphomas: CD44 variant isoforms are preferentially expressed in high-grade malignant lymphomas J Pathol 174 1994 89 100
24. S.H. Swerdlow International Agency for Research on Cancer, World Health Organization WHO classification of tumours of haematopoietic and lymphoid tissues 4th ed 2008 International Agency for Research on Cancer Lyon, France 240 241
25. S. Bhagavathi, A. Sharathkumar, and S. Hunter Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas Clin Neuropathol 27 2008 13 20
26. M. Montesinos-Rongen, A. Brunn, and S. Bentink Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell Leukemia 22 2008 400 405
27. C.O. Sung, S.C. Kim, and S. Karnan Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma Blood 117 2011 1291 1300
28. A. Junaid, M.C. Moon, G.E. Harding, and P. Zahradka Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1 Am J Physiol Cell Physiol 292 2007 C919 C926
29. A.A. Alizadeh, M.B. Eisen, and R.E. Davis Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 2000 503 511
30. H. Ponta, L. Sherman, and P.A. Herrlich CD44: from adhesion molecules to signalling regulators Nat Rev Mol Cell Biol 4 2003 33 45
31. K.M. Braaten, R.A. Betensky, and L. de Leval BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma Clin Cancer Res 9 2003 1063 1069
32. G. Kremmidiotis, J. Ridings, and M. Hicks Heterogeneity of CD44 expression among human B-cell subpopulations Tissue Antigens 51 1998 232 241
33. Y.H. Lin, and H.F. Yang-Yen The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway J Biol Chem 276 2001 46024 46030
34. S.R. Hamilton, S.F. Fard, and F.F. Paiwand The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells J Biol Chem 282 2007 16667 16680
35. C.A. Maxwell, J. McCarthy, and E. Turley Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? J Cell Sci 121 2008 925 932